Severe tophaceous gout and disability: changes in the past 15 years
- 239 Downloads
Epidemiologic data from recent decades show a significant increase in the prevalence and incidence of gout worldwide, in addition to changes in its clinical expression. Our objective was to compare the frequency of the severity of gout and disability in two patient groups at our clinic during different periods. We included and compared data of two groups: group A (1995–2000), patients from previous report, and group B (2010–2014), the baseline data of current patients participating in a cohort (GRESGO). This evaluation included data of socioeconomic and educational levels, demographics, associated diseases, previous treatment, clinical and biochemical data, and disability evaluated using the Health Assessment Questionnaire (HAQ). We included data of 564 gout patients. Participants were 35.7 ± 12.7 years old at onset and had 12.0 ± 9.2-years disease duration at their first evaluation in our department. Group B patients were younger, had higher educational and socioeconomic levels, and had more severe disease. However, this group had less frequency of some associated diseases and significantly higher HAQ scores. With increased HAQ score, a higher number of acute flares and tender, limited-to-motion, and swollen joints were seen. The spectrum of gout has changed over the past decade. A higher percentage of our patients had a severe form of disease, were younger, had earlier disease onset, and had more disability reflected in higher HAQ scores. In our current patient group, the variable most associated with disability was limited-to-motion joints; however, the number of acute flares and tender and swollen joints was also higher in patients with greater disability.
KeywordsDisability Gout HAQ Tophaceous gout
The GRESGO cohort received unrestricted, partial financial support from the Takeda Laboratories, the Dirección de Investigación of the Hospital General de México, and the Colegio Mexicano de Reumatología. We thank Maria Eugenia Sanchez Girard and Aarón Vázquez Mellado, research assistants for the GRESGO cohort.
Compliance with ethical standards
- 8.Perez-Ruiz F, Herrero-Beites A (2012) Changes in gout patient’s clinical profile in the last two decades. Arthritis Rheum 64(10 Suppl):S1–1216Google Scholar
- 13.Bronfman M, Guiscafre H, Castro V, Castro R, Gutierrez G (1988) La medición de la desigualdad: una estrategia metodológica, análisis de las características socioeconómicas de la muestra. Arch Invest Med 19:351–360Google Scholar
- 15.Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486–97Google Scholar
- 17.Trifirò G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M, Bianchini E, Medea G, Cricelli C, Caputi AP, Mazzaglia G (2013) Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study. Ann Rheum Dis 72(5):694–700CrossRefPubMedGoogle Scholar
- 18.Khanna D, Fitzgerald JD, Khanna PP, American College of Rheumatology, et al. (2012) American College of Rheumatology guidelines for management of gout. Part I: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64:1431–1445CrossRefGoogle Scholar
- 19.Peláez-Ballestas I, Boonen A, Vázquez-Mellado J, Reyes-Lagunes I, Hernández-Garduño A, Goycochea MV, Bernard-Medina AG, Rodríguez-Amado J, Casasola-Vargas J, Garza-Elizondo MA, Aceves FJ, Shumski C, Burgos-Vargas R, REUMAIMPACT group (2015) Coping strategies for health and daily-life stressors in patients with rheumatoid arthritis, ankylosing spondylitis, and gout: STROBE-compliant article. Medicine 94(10):e600. doi: 10.1097/MD.0000000000000600 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Scire CA, Mara M, Cimmino MA, Govoni M, Salaffi F, et al. (2013) Gout impacts on function and health-related quality life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR). Arthritis Res Ter 15(5):R101CrossRefGoogle Scholar
- 22.Goycochea MV, Sanin LH, Moreno J, Alvarez J, Burgos R, Garza M, et al. (2011) Validity of the COPCORD core questionnaire as a classification tool for rheumatic diseases. J Rheumatol 38:31–35Google Scholar